Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.41 |
| ▸ | ITK | Q08881 | 5/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | FES | P07332 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | ROS1 | P08922 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.37 |
| ▸ | FER | P16591 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359421 | 0.84 | MET (0.48) | METITKPLK4AURKAJAK2 | |
| SCHEMBL1357809 | 0.84 | MET (0.48) | METITKPLK4AURKAJAK2 | |
| SCHEMBL1359136 | 0.84 | MET (0.43) | METITKPLK4AURKAJAK2 | |
| SCHEMBL1358491 | 0.84 | MET (0.48) | METITKPLK4AURKAJAK2 | |
| SCHEMBL27910785 | 0.75 | MET (0.40) | METITKPLK4AURKAJAK2 | |
| SCHEMBL1358010 | 0.75 | MET (0.40) | METITKPLK4AURKAJAK2 | |
| SCHEMBL12140880 | 0.75 | MET (0.38) | METJAK2FGFR1FLT1HDAC3 | |
| SCHEMBL1357877 | 0.74 | JAK2 (0.38) | METITKPLK4AURKAJAK2 | |
| SCHEMBL1357897 | 0.74 | MET (0.43) | METITKPLK4AURKAJAK2 | |
| SCHEMBL1360011 | 0.74 | MET (0.41) | METITKPLK4AURKAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2569314-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
| WO-2011143645-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | MET 3/4885ITK 315/4885PLK4 293/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | MET 3/4885ITK 315/4885PLK4 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.